194 related articles for article (PubMed ID: 31136354)
1. Allergic Contact Dermatitis to Crisaborole.
Kimyon RS; Schlarbaum JP; Liou YL; Hylwa SA; Warshaw EM
Dermatitis; 2019; 30(4):272-274. PubMed ID: 31136354
[No Abstract] [Full Text] [Related]
2. Crisaborole: A new and effective nonsteroidal topical drug for atopic dermatitis.
Kailas A
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28834023
[No Abstract] [Full Text] [Related]
3. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
Callender VD; Alexis AF; Stein Gold LF; Lebwohl MG; Paller AS; Desai SR; Tan H; Ports WC; Zielinski MA; Tallman AM
Am J Clin Dermatol; 2019 Oct; 20(5):711-723. PubMed ID: 31264114
[TBL] [Abstract][Full Text] [Related]
4. Topical Agents for the Treatment of Atopic Dermatitis.
Eichenfield LF; Luger T; Papp K; Silverberg JI; Sierka D; Zang C; Tallman AM; Zielinski MA; Ports WC
J Drugs Dermatol; 2020 Jan; 19(1):50-64. PubMed ID: 31985912
[TBL] [Abstract][Full Text] [Related]
5. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Murrell DF; Gebauer K; Spelman L; Zane LT
J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor.
Pao-Ling Lin C; Gordon S; Her MJ; Rosmarin D
J Am Acad Dermatol; 2019 May; 80(5):1451-1453. PubMed ID: 30395914
[No Abstract] [Full Text] [Related]
7. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
Ono R; Yagi M; Shoji A; Fujita K; Yoshida M; Ports WC; Purohit VS
J Dermatol; 2020 Jan; 47(1):25-32. PubMed ID: 31657024
[TBL] [Abstract][Full Text] [Related]
10. Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
Uppal SK; Chat VS; Kearns DG; Wu JJ
J Drugs Dermatol; 2020 Oct; 19(10):956-959. PubMed ID: 33026767
[TBL] [Abstract][Full Text] [Related]
11. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Riahi A; Lam JM
Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
[TBL] [Abstract][Full Text] [Related]
12. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
Woo TE; Kuzel P
Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
[TBL] [Abstract][Full Text] [Related]
13. Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers.
Zane LT; Hughes MH; Shakib S
Am J Clin Dermatol; 2016 Oct; 17(5):519-526. PubMed ID: 27335049
[TBL] [Abstract][Full Text] [Related]
14. Contact allergy to crisaborole in a paediatric patient with atopic dermatitis.
Arora P; Neeley A
Contact Dermatitis; 2023 Oct; 89(4):309-310. PubMed ID: 37525478
[No Abstract] [Full Text] [Related]
15. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
Eichenfield LF; Call RS; Forsha DW; Fowler J; Hebert AA; Spellman M; Stein Gold LF; Van Syoc M; Zane LT; Tschen E
J Am Acad Dermatol; 2017 Oct; 77(4):641-649.e5. PubMed ID: 28823881
[TBL] [Abstract][Full Text] [Related]
16. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
Zane LT; Kircik L; Call R; Tschen E; Draelos ZD; Chanda S; Van Syoc M; Hebert AA
Pediatr Dermatol; 2016 Jul; 33(4):380-7. PubMed ID: 27193740
[TBL] [Abstract][Full Text] [Related]
17. Crisaborole, Dupilumab, and Sarilumab.
Hussar DA; Lee YF
J Am Pharm Assoc (2003); 2017; 57(5):640-643. PubMed ID: 28882252
[No Abstract] [Full Text] [Related]
18. Topical Crisaborole in the Treatment of Atopic Hand Dermatitis: A Retrospective Chart Review.
Kahn JS; Grossman-Kranseler JS; Zancanaro P; Griffiths D; Dumont N; Rosmarin D
Dermatitis; 2021 Nov-Dec 01; 32(6):e141-e143. PubMed ID: 34570730
[No Abstract] [Full Text] [Related]
19. 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis.
Ciaravino V; Coronado D; Lanphear C; Chanda S
J Dermatol Sci; 2017 Aug; 87(2):116-122. PubMed ID: 28416366
[TBL] [Abstract][Full Text] [Related]
20. Crisaborole 2% Ointment (Eucrisa
Gupta AK; Versteeg SG; Abramovits W; Vincent KD
Skinmed; 2017; 15(5):377-380. PubMed ID: 29139367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
